Publications Related to Cancer

Katsuno Y, Qin J, Oses-Prieto J, Wang H, Jackson-Weaver O, Zhang T, Lamouille S, Wu J, Burlingame A, Xu J, Derynck R. (2018). Arginine methylation of SMAD7 by PRMT1 in TGF-β-induced epithelial-mesenchymal transition and epithelial stem-cell generation. Journal of Biological Chemistry 293: 13059-72.

James CC, Zeitz MJ, Calhoun PJ, Lamouille S, Smyth JW. (2018). Altered translation initiation of Gja1 limits gap junction formation during epithelial-mesenchymal transition. Molecular Biology of the Cell 29(7): 773-880.

Pridham KJ, Varghese RT, Sheng Z. (2017). The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma. Frontiers in Oncology 7(312).

Pridham KJ, Le L, Guo S, Varghese RT, Algino S, Liang Y, Fajardin R, Rodgers CM, Simonds GR, Kelly DF, Sheng Z. (2017). PIK3CB/p110β is a Selective Survival Factor for Glioblastoma. Neuro-Oncology.

Varghese RT, Lian Y, Guan T, Franck CT, Kelly DF, Sheng Z. (2016). Survival kinase genes present prognostic significance in glioblastoma. Oncotarget.

Murphy SF, Varghese RT, Lamouille S, Guo S, Pridham KJ, Kanabur P, Osimani AM, Sharma S, Jourdan J, Rodgers CM, Simonds GR, Gourdie RG, Sheng Z. (2016). Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide. Cancer Research 76(1): 139-49.

O'Malley PW, Mulla ZD, Nesic O. (2015). Multiple sclerosis and breast cancer. J Neurol Sci 356(12): 137-41.

Li T, Murphy S, Kiselev B, Bakshi KS, Zhang J, Eltahir A, Zhang Y, Chen Y, Zhu J, Davis RM, Madsen LA, Morris JR, Karolyi DR, LaConte SM, Sheng Z, Dorn HC. (2015). A New Interleukin-13 Amino-Coated Gadolinium Metallofullerene Nanoparticle for Targeted MRI Detection of Glioblastoma Tumor Cells. Journal of the American Chemical Society 137(24): 7881-8.

Pohlmann ES, Patel K, Guo S, Dukes MJ, Sheng Z, Kelly DF. (2015). Real-time visualization of nanoparticles interacting with glioblastoma stem cells. Nano Letters 15(4): 2329-35.

Guptarak J, Wiktorowicz JE, Sadygov RG, Zivadinovic D, Paulucci-Holthauzen AA, Vergara L, Nesic O. (2014). The cancer drug tamoxifen - a potential therapeutic treatment for spinal cord injury. J Neurotrauma 31(3): 268-83.

Katsuno Y, Lamouille S, Derynck R. (2013). TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Current Opinion in Oncology 25(1).

Tenga MJ, Lazar IM. (2012). A proteomic snapshot of breast cancer cell cycle: the G1/S transition point. Proteomics.

Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A. (2012). MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. The Journal of Experimental Medicine 209(4): 679-96.

Whitney JR, Sarkar S, Zhang J, Do T, Young T, Manson MK, Campbell TA, Puretzky AA, Rouleau CM, More KL, Geohegan DB, Rylander CG, Dorn HC, Rylander MN. (2011). Single walled carbon nanohorns as photothermal cancer agents. Laser in Surgery and Medicine 43(1): 43-51.

Sheng Z, Evans KS, and Green MR. (2010). An activating transcription factor 5-mediated survival pathway as a target for cancer therapy. Oncotarget 1(6): 457-460.

Armenta JM, Perez M, Yang X, Shapiro D, Reed D, Tuli L, Finkielstein CV, Lazar IM. (2010). Fast proteomic protocol for biomarker fingerprinting in cancerous cells. Journal of Chromatography A 1217(17): 2862-70.

Srivastava S, Moraes CT. (2009). Cellular adaptations to oxidative phosphorylation defects in cancer. In: S.P. Apte and R. Sarangarajan (Ed.), Cellular Respiration and Carcinogenesis. (pp. 55-72):New York, NY: Humana Press.